Ocular Therapeutix (OCUL) Current Deferred Revenue (2013 - 2026)

Ocular Therapeutix has reported Current Deferred Revenue for 9 years, with the latest figure at $14.0 million in Q2 2026.

• Current Deferred Revenue for Q2 2026 came in at $14.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Jun 2026 was $14.0 million (changed 0.0% YoY), and the FY2025 annual result was $14.0 million, down 0.91% from the prior year.
• Current Deferred Revenue was little changed at $14.0 million in Q2 2026, from $14.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $14.6 million in Q2 2023 and troughed at $13.8 million in Q1 2023.
• A 5-year average of $14.2 million and a median of $14.1 million in 2022 frame the typical range for Current Deferred Revenue.
• The widest annual swing landed in 2022, when Current Deferred Revenue climbed 7.41%; it then fell 3.55% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $14.0 million in 2022, then gained by 3.06% to $14.4 million in 2023, then retreated by 1.82% to $14.1 million in 2024, then retreated by 0.91% to $14.0 million in 2025, then changed by 0.0% to $14.0 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $14.0 million in Q2 2026, $14.0 million in Q1 2026, and $14.0 million in Q4 2025.